about
Peptides that bind the HIV-1 integrase and modulate its enzymatic activity--kinetic studies and mode of actionBroad antiretroviral activity and resistance profile of the novel human immunodeficiency virus integrase inhibitor elvitegravir (JTK-303/GS-9137)Posttranslational acetylation of the human immunodeficiency virus type 1 integrase carboxyl-terminal domain is dispensable for viral replicationEfficacy, safety, and patient acceptability of elvitegravir/cobicistat/emtricitabine/tenofovir in the treatment of HIV/AIDSMultifunctional facets of retrovirus integraseIntegrase Inhibitor Prodrugs: Approaches to Enhancing the Anti-HIV Activity of β-Diketo AcidsActivities, Crystal Structures, and Molecular Dynamics of Dihydro-1 H -isoindole Derivatives, Inhibitors of HIV-1 IntegraseLong-term efficacy and safety of raltegravir in the management of HIV infection.Dolutegravir(DTG, S/GSK1349572) combined with other ARTs is superior to RAL- or EFV-based regimens for treatment of HIV-1 infection: a meta-analysis of randomized controlled trialsA historical sketch of the discovery and development of HIV-1 integrase inhibitorsStructure-analysis of the HIV-1 integrase Y143C/R raltegravir resistance mutation in association with the secondary mutation T97AUnprocessed viral DNA could be the primary target of the HIV-1 integrase inhibitor raltegravirBF integrase genes of HIV-1 circulating in São Paulo, Brazil, with a recurrent recombination regionSubstrate recognition and motion mode analyses of PFV integrase in complex with viral DNA via coarse-grained modelsNon-catalytic site HIV-1 integrase inhibitors disrupt core maturation and induce a reverse transcription block in target cellsMolecular features related to HIV integrase inhibition obtained from structure- and ligand-based approachesEffect of Ethanol on the Metabolic Characteristics of HIV-1 Integrase Inhibitor Elvitegravir and Elvitegravir/Cobicistat with CYP3A: An Analysis Using a Newly Developed LC-MS/MS MethodA novel anti-HIV active integrase inhibitor with a favorable in vitro cytochrome P450 and uridine 5'-diphospho-glucuronosyltransferase metabolism profile.In-Silico docking of HIV-1 integrase inhibitors reveals a novel drug type acting on an enzyme/DNA reaction intermediate.Screening for antiviral inhibitors of the HIV integrase-LEDGF/p75 interaction using the AlphaScreen luminescent proximity assay.An unusual helix turn helix motif in the catalytic core of HIV-1 integrase binds viral DNA and LEDGF.Host sequence motifs shared by HIV predict response to antiretroviral therapyPharmacokinetics and safety of S/GSK1349572, a next-generation HIV integrase inhibitor, in healthy volunteers.The HIV-1 integrase mutations Y143C/R are an alternative pathway for resistance to Raltegravir and impact the enzyme functions.Subunit-specific protein footprinting reveals significant structural rearrangements and a role for N-terminal Lys-14 of HIV-1 Integrase during viral DNA bindingCritical appraisal of elvitegravir in the treatment of HIV-1/AIDS.Dolutegravir: clinical efficacy and role in HIV therapy.Analysis of pol integrase sequences in diverse HIV type 1 strains using a prototype genotyping assay.The HIV-1 integrase α4-helix involved in LTR-DNA recognition is also a highly antigenic peptide elementHIV-1 IN inhibitors: 2010 update and perspectivesMechanisms and inhibition of HIV integrationBiochemical and pharmacological analyses of HIV-1 integrase flexible loop mutants resistant to raltegravirAntiretroviral therapy in the clinicSolution conformation and dynamics of the HIV-1 integrase core domain.Rous sarcoma virus synaptic complex capable of concerted integration is kinetically trapped by human immunodeficiency virus integrase strand transfer inhibitors.Pharmacokinetics and dose-range finding toxicity of a novel anti-HIV active integrase inhibitor.Resistance to integrase inhibitors.Bicyclic hydroxy-1H-pyrrolopyridine-trione containing HIV-1 integrase inhibitors.Secondary integrase resistance mutations found in HIV-1 minority quasispecies in integrase therapy-naive patients have little or no effect on susceptibility to integrase inhibitors.S/GSK1349572, a new integrase inhibitor for the treatment of HIV: promises and challenges.
P2860
Q24316120-8B91681E-E768-4CF0-B035-570FCFA634A0Q24656978-DE3A15F5-F98D-47A6-912B-58D0C8A86A77Q24672416-CD806DEA-04DD-479A-A3BD-ADA491E4132CQ26783253-48A3FE97-BE76-4F44-A9AA-AD5F31709E1FQ26795766-7F43AA59-4870-467A-B810-668356426B74Q26800036-5AAA6A10-BA8F-41B2-9468-C1B26F7392CEQ27674615-B21E1EAF-A808-4540-8FA1-8840727C9072Q27686870-B2D32998-CE42-4BA2-B7D1-1D4743C5842EQ28077053-5C6BB0E9-EA11-4D93-AACC-965EA286BA7CQ28274166-EA6EF98F-4BCE-42CC-A5E5-68A4841EF8E0Q28478722-400865D3-1529-4C9B-B86F-A4CDE2F1DCE3Q28480958-C6B05413-96B3-4B9E-B3D6-6E8BDB52BDEEQ28482075-3704DCE0-F462-49CA-8C4C-6165EDB168D4Q28485284-DDAFEEC8-2C28-4CEA-8E56-BB99A1187EDEQ28536951-40F72F9E-651B-4D22-AF15-002DDEDD88C5Q28538414-8E22E4EB-20B1-4AE8-B739-7327B4E3E36AQ28550189-81A92F82-FA77-461F-B5CF-110C7D76CC7FQ30429621-D35D9D9D-6AD0-4E9C-8236-69D276823C24Q30479242-E54D5D04-5382-4586-92A5-BC86AB8DA51AQ33334795-5B8F5EC1-B7F2-4E63-A32A-EB37DB9AEB39Q33396954-FD423CC4-4931-486C-B666-75146DB19FACQ33486144-7EB06827-BE8F-4328-9ECC-3A878120D707Q33559015-9C673342-6A2D-4D43-B1AA-6A8367980FA6Q33570427-5D6D79F2-473E-4F72-8E6D-7F8A2CDE9323Q33589910-478B0813-7F0C-4602-9B9A-F4D5415B8BF8Q33680234-494395B7-C5DC-4210-A9E8-966F7D7C4D08Q33725024-8A01735B-8AE0-4EDF-86D3-FEE90F949589Q33786200-118CC830-85B2-41AF-A0C6-B5F33A26C894Q33786815-B47AEF52-B1F9-4E01-987D-F09194B0CC92Q33814351-0FB44797-7F9B-4B23-B88E-585D4F0B115DQ33814406-BC18A156-DE69-426D-9A78-89BCAE2B5A06Q33838063-E604713D-9CAD-497A-B183-8E812B4EA793Q33877347-112A6E69-E1E1-4EA5-9350-41F4BC0B12C7Q33885382-F0C2BEEE-8F86-4B66-899B-A45ECA9DC76BQ33888602-6FCF6D4B-DA7E-4D4C-B10F-571C3C039D42Q33911400-42693461-4794-424C-9AFD-A7B63B0D0C4FQ34059896-96A7D9B7-3E77-44EA-9BA0-9D8CA4641865Q34080214-E9A108AE-CA06-4897-8268-C94482AEC56BQ34108775-F5B89E17-3610-4767-9344-53A8EE3488ECQ34168983-7ED25CBF-0281-404B-9A80-33A488329272
P2860
description
2005 nî lūn-bûn
@nan
2005 թուականի Մարտին հրատարակուած գիտական յօդուած
@hyw
2005 թվականի մարտին հրատարակված գիտական հոդված
@hy
2005年の論文
@ja
2005年論文
@yue
2005年論文
@zh-hant
2005年論文
@zh-hk
2005年論文
@zh-mo
2005年論文
@zh-tw
2005年论文
@wuu
name
Integrase inhibitors to treat HIV/AIDS.
@ast
Integrase inhibitors to treat HIV/AIDS.
@en
Integrase inhibitors to treat HIV/AIDS.
@nl
type
label
Integrase inhibitors to treat HIV/AIDS.
@ast
Integrase inhibitors to treat HIV/AIDS.
@en
Integrase inhibitors to treat HIV/AIDS.
@nl
prefLabel
Integrase inhibitors to treat HIV/AIDS.
@ast
Integrase inhibitors to treat HIV/AIDS.
@en
Integrase inhibitors to treat HIV/AIDS.
@nl
P356
P1476
Integrase inhibitors to treat HIV/AIDS.
@en
P2093
Allison A Johnson
Christophe Marchand
P2888
P304
P356
10.1038/NRD1660
P50
P577
2005-03-01T00:00:00Z